acute myeloid leukemia

[GlycoMimetics, Inc] GlycoMimetics, Inc. has announced that clinicians at University of California Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-naïve acute myeloid leukemia.

[Vor Biopharma] Vor Biopharma, a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer, announced the formation of a collaboration with Janssen Biotech, Inc.

[Nature Cancer] Researchers identified the RNA-binding protein RNA-binding motif protein, X-linked, and its retrogene RBMXL1 to be required for murine and human myeloid leukemogenesis.

[Trillium Therapeutics, Inc.] Trillium Therapeutics, Inc. announced that it has dosed the first acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.

[Expert Review of Hematology] Luspatercept is a promising alternative to ESAs for a subset of transfusion-dependent patients with lower risk myelodysplastic syndromes, namely those with a sideroblastic phenotype who are either not suitable for or have already failed erythropoietin-based treatment.

[Blood Cancer Journal] The authors summarize the evolution of acute promyelocytic leukemia (APL) therapy, focusing on key milestones that led to the standard-of-care APL therapy available today and discuss treatment algorithms and management tips to minimize induction mortality.